Talphera, Inc. (TLPH)

Market Cap	10.07M
Revenue (ttm)	27,000
Net Income (ttm)	-11.64M
Shares Out	20.50M
EPS (ttm)	-0.44
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	21,617
Open	0.4910
Previous Close	0.4901
Day's Range	0.4800 - 0.5119
52-Week Range	0.4500 - 1.1900
Beta	-0.15
Analysts	Strong Buy
Price Target	6.00 (+1,124.49%)
Earnings Date	May 14, 2025

About TLPH

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company’s lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, a nafamostat formulation for direct IV infusion as an investigational product for various indications, such as antiviral, acute respiratory distress syndrome, disseminated ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 14, 2011
• Employees: 13
• Stock Exchange: NASDAQ
• Ticker Symbol: TLPH
• Website: https://talphera.com

Analyst Forecast

According to one analyst, the rating for TLPH stock is "Strong Buy" and the 12-month stock price forecast is $6.0.

Price Target

$6.0

(1,124.49% upside)

Analyst Consensus: Strong Buy